CAN FITE BIOPHARMA LTD-ADR (CANF) Stock Price, Forecast & Analysis
USA - NYSEARCA:CANF - US13471N3008 - ADR
CANF Key Statistics, Chart & Performance
The current stock price of CANF is 0.3751 USD. In the past month the price decreased by -26.67%. In the past year, price decreased by -80.24%.
CANF Latest News, Press Relases and Analysis
CANF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25.28 | 422.08B | ||
| AMGN | AMGEN INC | 15.7 | 184.85B | ||
| GILD | GILEAD SCIENCES INC | 15.58 | 158.30B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.31 | 112.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.82 | 75.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.35 | 59.52B | ||
| INSM | INSMED INC | N/A | 41.20B | ||
| NTRA | NATERA INC | N/A | 28.34B | ||
| BIIB | BIOGEN INC | 9.99 | 24.51B | ||
| INCY | INCYTE CORP | 16.69 | 20.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.73 | 21.16B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.87 | 14.46B |
Related stock screener links
About CANF
Company Profile
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Company Info
CAN FITE BIOPHARMA LTD-ADR
10 Bareket Street, Kiryat Matalon, P.O. Box 7537
Petah Tikva 4951778 IL
CEO: Pnina Fishman
Employees: 5
Phone: 97239241114
CAN FITE BIOPHARMA LTD-ADR / CANF FAQ
Can you describe the business of CAN FITE BIOPHARMA LTD-ADR?
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The firm co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Can you provide the latest stock price for CAN FITE BIOPHARMA LTD-ADR?
The current stock price of CANF is 0.3751 USD. The price decreased by -3.12% in the last trading session.
What is the dividend status of CAN FITE BIOPHARMA LTD-ADR?
CANF does not pay a dividend.
What is the ChartMill technical and fundamental rating of CANF stock?
CANF has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of CAN FITE BIOPHARMA LTD-ADR (CANF) based on its PE ratio?
CAN FITE BIOPHARMA LTD-ADR (CANF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.72).
Can you provide the number of employees for CAN FITE BIOPHARMA LTD-ADR?
CAN FITE BIOPHARMA LTD-ADR (CANF) currently has 5 employees.
What is CAN FITE BIOPHARMA LTD-ADR worth?
CAN FITE BIOPHARMA LTD-ADR (CANF) has a market capitalization of 6.40M USD. This makes CANF a Nano Cap stock.
CANF Technical Analysis
CANF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CANF. While CANF seems to be doing ok healthwise, there are quite some concerns on its profitability.
CANF Financial Highlights
Over the last trailing twelve months CANF reported a non-GAAP Earnings per Share(EPS) of -0.72. The EPS increased by 40% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -102.07% | ||
| ROE | -188.34% | ||
| Debt/Equity | 0 |
CANF Forecast & Estimates
7 analysts have analysed CANF and the average price target is 4.7 USD. This implies a price increase of 1153.59% is expected in the next year compared to the current price of 0.3751.